Aims To compare the inhibitory potential of the HIV protease inhibitors saquinavir, ritonavir and indinavir against CYP1A2, CYP2C9, CYP2E1 and CYP3A4 catalysed metabolic reactions in human liver microsomes in vitro. Methods Microsomes from six human livers were utilized in this study. The probe substrates were phenacetin (CYP1A2), tolbutamide (CYP2C9), chlorzoxazone (CYP2E1) and testosterone (CYP3A4). Metabolites were analysed by high performance liquid chromatography. IC 50 (concentration of inhibitor giving 50% decrease in enzyme activity) and, where appropriate, K i values were calculated. Results Ritonavir was a very potent inhibitor of CYP3A4 mediated testosterone 6b-hydroxylation (mean K i =0.019±0.004 mm, mean±s.d.; n=6) and also inhibited tolbutamide hydroxylation (IC 50 =4.2±1.3 mm, mean±s.d.; n=6). Inhibition of phenacetin O-deethylation and chlorzoxazone 6-hydroxylation was negligible. Indinavir was an order-of-magnitude less potent in inhibiting CYP3A4 (K i = 0.17±0.01 mm) and did not produce appreciable inhibition of the CYP1A2, CYP2C9 or CYP2E1 catalysed reactions. Saquinavir was the least potent CYP3A4 inhibitor (K i =2.99±0.87 mm) and produced some inhibition of CYP2C9 (approximately 50% at 50 mm). Conclusions The HIV protease inhibitors have differential effects on CYP isozymes. There is obvious potential for clinically significant drug interactions particularly with ritonavir. Pharmacokinetic drug interaction studies are crucial to gain an overall understanding of the beneficial and potentially harmful effects of this important group of drugs.
Introduction co-administered drugs [9, [12] [13] [14] . Ritonavir has recently been reported to increase the area under the plasma The three major genes (env, gag and pol) of human immunodeficiency virus type 1 (HIV-1) encode polyproteins concentration-time curve of saquinavir by more than 20-fold [14] in a group of HIV+ patients. (gp160, gag and gag-pol) which undergo post-translational proteolytic processing by either cellular [1] 
or virally
The aim of the present work was to compare the effect of ritonavir, saquinavir and indinavir on different CYP encoded proteinase enzymes [2] . Considerable effort has been expended in recent years in the development of isoforms in human liver microsomes in vitro. The following probe substrates were used: phenacetin (CYP1A2 [15] ), inhibitors of the virally-encoded protease of HIV. If this enzyme is non-functional, immature non-infectious virions tolbutamide (CYP2C9 [16] ), chlorzoxazone (CYP2E1 [17] ) and testosterone (CYP3A4 [18] ). are produced. Initial clinical studies suggest that the protease inhibitors are very potent anti-HIV drugs with the three compounds licensed for use ritonavir, saquinavir and indinavir all reported to produce marked reductions in Methods plasma viral load, particularly when used in combination with nucleoside analogue reverse transcriptase inhibitors Chemicals [3] [4] [5] [6] [7] [8] . However, there are important pharmacokinetic issues Phenacetin, paracetamol, metacetamol, tolbutamide, chlorrelating to the use of protease inhibitors. For example, zoxazone, zoxazolamine, testosterone, 6b-OH testosterone, bioavailability appears to be limited with several compounds, 11b-OH testosterone and b-NADPH (reduced form) were most notably saquinavir, due to substantial first-pass metabpurchased from the Sigma Chemical Company (Poole, olism by CYP3A4 [9] . Both ritonavir and indinavir are also Dorset, U.K.). 6-Hydroxychlorzoxazone was purchased metabolised by CYP3A4 [10, 11] and in addition, ritonavir from Ultrafine Chemicals (Salford, UK). Chlorpropamide is a potent inhibitor of CYP3A-mediated reactions [10] and 4-OH tolbutamide were gifts from Hoechst AG (Frankfurt, Germany); ritonavir was a gift from Abbott Roche Products Ltd. (Welwyn Garden City, UK) and 6-hydroxychlorzoxazone and zoxazolamine from a standard curve of known 6-hydroxychlorzoxazone concentrations indinavir was a gift from Merck (West Point, USA original run conditions at 20 min. This was followed by a 5 min re-equilibration period. The inter-and intra-assay obtained from the donor's relatives and Ethics Committee approval was granted for their use in this study. Liver tissue coefficients of variation were 5.3 and 8.5% respectively determined at 3 nmol hydroxychlorzoxazone. The lower (10-20g portions) was frozen in liquid nitrogen and stored at -80°C until required. Washed microsomes (105,000g limit of determination was 100 pmol. pellets) were prepared from human liver samples by the classical differential centrifugation technique and microsomal
Testosterone 6b-hydroxylation A 500 ml incubation contained 0.05 mg microsomal protein, testosterone, MgCl 2 (10 mm) protein yield was determined by the method of Lowry et al. [19] using bovine serum albumin as standard.
and NADPH (2.5 mm) in 0.067 m phosphate buffer. The reaction was terminated by the addition of 11b-hydroxytestosterone as internal standard and immediate Enzyme assays for CYP probes extraction with DCM (10 ml; 20 min). The DCM layer was then evaporated to dryness and reconstituted with Phenacetin O-deethylation A 500 ml reaction mixture typically contained 0.5 mg microsomal protein, phenacetin mobile phase (200 ml) prior to h.p.l.c. analysis. Briefly, a 50 ml aliquot was injected onto a 5 mC 18 Prodigy column (20 mm), MgCl 2 (10 mm) and NADPH (2.5 mm) in 0.067 m phosphate buffer (pH 7.4). Metacetamol was added as (15 cm×4.6 mm; Phenomenex, Macclesfield, UK) and separated from 11b-hydroxytestosterone, testosterone and internal standard and samples extracted with DCM (10 ml; 20 min) to remove unmetabolized phenacetin followed by other metabolites by a gradient mobile phase system comprising of solvent mixtures: mixture A 35:64:1 methanethyl acetate (10 ml; 20 min). Samples were evaporated to dryness and reconstituted in mobile phase (200 ml) prior to ol:distilled water:AcN (v:v:v) and mixture B 80:18:2 methanol:distilled water:AcN (v:v:v). Initial run conditions h.p.l.c. analysis. Paracetamol and metacetamol were separated using a mobile phase (flow rate 1 ml min −1 ) consisting of were 75% A: 25% B. Between 9 and 28 min there was a linear increase of solvent B to 75% (25% A) remaining so 10% AcN: 90% sodium phosphate buffer (0.1m; pH 4.3; v:v) and a Spherex 5 mC 18 column (25 cm×4.6 mm; until 30 min. Between 30 and 32 min there was a linear decrease back to the starting run conditions (25% A: 75% Phenomenex, Macclesfield, UK) with u.v. detection at 254 nm. Paracetamol formation was quantified by interpolat-B) with a 3 min re-equilibration period. U.v. detection was at 254 nm. The inter-and intra-assay coefficients of variation ing peak height ratios of paracetamol and metacetamol from a standard curve of known paracetamol concentrations.
were 5.6% and 4.3% respectively, determined at 500 pmol 6b-hydroxytestosterone. The assay had a lower limit of Inter-and intra-assay coefficients of variation were 8.7% and 6.5% respectively determined at 100 pmol paracetamol. The determination of 50 pmol. lower limit of determination was 25 pmol.
Inhibitor studies A range of protease inhibitor concentrations (up to 100 mm) were screened against a single concentration Tolbutamide 4-hydroxylation A 500 ml reaction mixture contained 0.5 mg microsomal protein, tolbutamide of each probe substrate. IC 50 values (i.e. concentration producing 50% inhibition of control enzyme activity were (100 mm). MgCl 2 (10 mm ) and NADPH (1 mm) in 0.067 m phosphate buffer ( pH 7.4). Termination, extraction of determined (where appropriate) for each compound using an iterative program GRAFIT 3.0 (Erithacus Software Ltd). samples and h.p.l.c. conditions were as previously described [20] . The inter-and intra-assay coefficients of In addition, the apparent K i was determined for each of the protease inhibitors with testosterone as substrate (concenwere 3% and 1.3% respectively determined at 0.6 nmol hydroxytolbutamide. The lower limit of determination trations of testosterone 50-400 mm) by substituting K m and V max values in the appropriate equations. All kinetic studies was 20 pmol.
were performed under linear conditions with respect to time and protein concentration. Chlorzoxazone 6-hydroxylation A 500 ml incubation volume contained 0.2 mg microsomal protein, chlorzoxazone (100 mm), MgCl 2 (10 mm) and NADPH (1 mm) in 0.067 m Results phosphate buffer (pH 7.4). The reaction was terminated by the addition of zoxazolamine as internal standard and
The six human livers used in this study were from patients (4M; 2F) between 10-41 years old. The protease inhibitors extracted with DCM (5 ml; 10 min). The organic phase was evaporated to dryness and reconstituted into mobile phase had differential effects on the CYP isoforms (Table 1, Figure 1 ). Ritonavir was an extremely potent inhibitor (200 ml) prior to h.p.l.c. analysis. Metabolite formation was quantified by interpolating peak height ratios of of CYP3A4 catalysed testosterone 6-hydroxylation with an IC 50 of 53.9±9.9 mm but had negligible inhibitory (40% and 20% decrease in enzyme activity at 100 mm respectively). Indinavir was an order of magnitude less effect on CYP1A2 or CYP2E1.
inhibitors are substrates for CYP3A4 their metabolism may Discussion be induced by drugs such as rifampicin, rifabutin and carbamazepine [30] . The development of the protease inhibitors represents a significant advance in the treatment of HIV infection.
There is an additional aspect to the drug interaction portfolio of ritonavir. Recent data suggest that in addition Potent suppression of virus replication to levels below detection in plasma have been achieved [21, 22] and to being a potent inhibitor of CYP isozymes it also may induce CYP1A2 (as shown by a 43% decrease in steady state eradication of virus has now become an acceptable hypothesis to test [23] . However, there are important pharmacokinetic theophylline concentrations [31] ) and glucuronyl transferase (as shown by a 40% decrease in ethinyloestradiol AUC issues to be considered prior to the widespread use of these new anti-HIV drugs.
[32]). It seems certain that with new protease inhibitors in various stages of clinical development (e.g. nelfinavir, Ritonavir is one of the most potent inhibitors of CYP3A. Kumar et al. [10] reported IC 50 values in human liver 141W94), drug interaction studies will be crucial to gain an overall understanding of the beneficial and potentially microsomes of 0.07, 0.14 and 2 mm for nifedipine oxidation, terfenadine hydroxylation and ethinyloestradiol harmful effects of this important group of drugs. 2-hydroxylation respectively. In the present study the K i value for ritonavir against testosterone 6b-hydroxylation was
We are grateful to the MRC and Roche Products Ltd. for estimated to be 0.019 mm which is equal to or less than the financial support. reported K i values for the well documented CYP3A4 inhibitor ketoconazole ie 0.015 mm for nifedipine oxidation [24] hydroxylamine [9] . On the other hand, since protease
